Meu-cinn for Gastric Mucosal Health in Adults With Functional Dyspepsia

Inclusion Criteria:

• Rome IV-based functional dyspepsia-

Exclusion Criteria:

• Patients with gastrointestinal symptoms requiring immediate drug treatment.

• Individuals with a history of hypersecretory gastric disorders likeZollinger-Ellison syndrome.

• Individuals who received Helicobacter pylori eradication therapy within 4 weeksprior to the trial.

• Individuals who have taken nonsteroidal anti-inflammatory drugs, steroids,antibiotics, aspirin, antithrombotic agents, or acid suppressants within the lastmonth.

• Individuals with a history of upper gastrointestinal surgery, stricture, bleeding,or procedures like esophageal dilation or mucosal resection within the last year.

• Individuals with gastric ulcers (active or healing), duodenal ulcers (active orhealing), reflux esophagitis (LA grade A or higher), or malignant tumors identifiedwithin the last 6 months through endoscopy.

• Patients with uncontrolled hypertension (resting BP ≥160/100 mmHg).

• Patients with uncontrolled diabetes (fasting glucose ≥160 mg/dL).

• Individuals with creatinine levels ≥ 2 times the upper limit of normal at theresearch institution.

• Individuals with aspartate aminotransferase or alanine aminotransferase levels ≥ 2times the upper limit of normal at the research institution.

• Alcohol abusers.

• Individuals taking medications for psychiatric disorders (except those takingintermittent medication for sleep disorders).

• Pregnant or breastfeeding women or those planning to become pregnant during theclinical trial period.

• Individuals with allergies to any components of the study foods.

• Individuals who participated in or plan to participate in another drug clinicaltrial within the last month.

• Individuals deemed unsuitable for the study by the investigator for other reasons.